- Home
- CVR vs MYNZ Comparison
CVR vs MYNZ Comparison
Compare CVR & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVR | MYNZ |
|---|---|---|
| Founded | 1920 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 10.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVR | MYNZ |
|---|---|---|
| Price | $13.98 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 3.8K | ★ 402.7K |
| Earning Date | 03-27-2026 | 09-26-2025 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,008,045.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.15 | $0.60 |
| 52 Week High | $15.18 | $7.80 |
Technical Indicators
Market Signals| Indicator | CVR | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 32.15 |
| Support Level | $13.31 | $0.70 |
| Resistance Level | $13.98 | $1.37 |
| Average True Range (ATR) | 0.62 | 0.13 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 83.16 | 25.97 |
Price Performance
Historical ComparisonAbout CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.